VanEck Biotech ETF (BBH) Covered Calls

The VanEck Biotech ETF (BBH) is an exchange-traded fund that seeks to replicate the price and yield performance of the MVIS US Listed Biotech 25 Index. The fund provides concentrated exposure to the largest and most liquid companies in the biotechnology industry, including firms involved in genetic analysis, diagnostic equipment, and drug development. BBH is designed for investors seeking targeted, large-cap growth potential within the healthcare sector.

You can sell covered calls on VanEck Biotech ETF to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BBH (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

The VanEck Biotech ETF (BBH) is a passively managed exchange-traded fund that tracks the MVIS US Listed Biotech 25 Index. This index is specifically designed to follow the performance of the most influential companies in the biotechnology space. Unlike broader healthcare funds, BBH provides a concentrated portfolio of approximately 25 stocks, focusing on companies that derive at least 50% of their revenue from biotechnology-related activities. This results in a high-conviction vehicle that captures the growth of genomics, molecular diagnostics, and specialized therapeutic development.

The fund's weighting methodology ensures that it is dominated by large-cap industry leaders, making it less volatile than equal-weighted biotech peers that lean into speculative small-cap firms. By focusing on established entities with significant research and development pipelines and proven commercial products, BBH offers a more institutional-grade approach to a traditionally high-risk sector. The fund is diversified across several sub-industries, including pharmaceutical manufacturing, laboratory apparatus, and medical research services.

Competitive Landscape

In the biotechnology ETF market, BBH competes primarily with larger, more diversified products. Its most significant rival is the iShares Biotechnology ETF, which tracks a much broader index of over 200 companies. While IBB offers wider market coverage, BBH's concentrated approach often appeals to investors looking for deeper exposure to the sector's "blue-chip" names. Another major competitor is the SPDR S&P Biotech ETF, which utilizes an equal-weighted strategy that gives more influence to smaller, emerging biotech firms.

The strength of BBH is found in its top holdings, which include some of the most successful companies in medical history. Major constituents such as Amgen Inc. and Gilead Sciences, Inc. provide the fund with a foundation of steady cash flows and dividends. Other key holdings like Vertex Pharmaceuticals Incorporated and Regeneron Pharmaceuticals, Inc. offer exposure to breakthrough treatments in rare diseases and oncology. All these underlying companies are listed on major exchanges and feature highly liquid options markets.

Strategic Outlook and Innovation

The strategic value of BBH is tied to the accelerating pace of innovation in the "Bio-Revolution." The industry is currently benefiting from the convergence of artificial intelligence and drug discovery, which is significantly shortening the timeline for bringing new therapies to market. As Large Language Models and specialized AI tools become integrated into the R&D process, the large-cap leaders held within BBH are best positioned to acquire or develop these technologies to maintain their competitive moats.

Furthermore, the sector is supported by structural tailwinds, including an aging global population and an increasing prevalence of chronic diseases. The push toward personalized medicine—where treatments are tailored to an individual's genetic profile—is creating new, high-margin revenue streams for the firms that dominate genetic sequencing and molecular diagnostics. As regulatory environments continue to evolve to support faster approvals for life-saving drugs, BBH remains a core vehicle for investors looking to participate in the long-term secular growth of global healthcare infrastructure.

Want more examples? BBEU Covered Calls | BBIO Covered Calls